Alimta Articles
NICE draft guidance rejects Eli Lilly's Alimta for NSCLC maintenance
22 February 2013
Nexavar use in Chinese patients nearly doubled in 2012
19 December 2012
FDA clears new use for Eli Lilly's Alimta
19 October 2012
More news from ASCO meeting
5 June 2012
Lilly’s Alimta shows benefit in hard-to-treat lung cancer patients
28 September 2011
Eli Lilly’s Alimta gains backing from UK’s NICE as maintenance therapy for advanced, non-squamous NSCLC
7 April 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Data uncertainties mean NICE unable to recommend pemetrexed for NSCLC maintenance treatment
17 December 2009
Eli Lilly 3rd quarter 2009 beats forecasts, raises guidance
22 October 2009
Boehringer Ingelheim to start Ph II study with Tovok
4 August 2009
Japan: no added use for Nexavar, Alimta
27 May 2009
Lilly's 1st-qtr profit jumps 23.6% to $1.31B
29 April 2009
SCLC drug market wil more than double to $648M in 2017
14 April 2009
Lilly swings to loss on ImClone acquisition
9 February 2009
Highlights of first PDCO meeting of 2009
26 January 2009
AZ has mixed bag of results from Ph III trials
24 November 2008
EntreMed achieves endpoint in NSCLC study
17 November 2008
Lilly swings into loss in 3rd qtr on legal costs
3 November 2008
Lilly gets third appro for Alimta
6 October 2008
Scotland's NHS backs MabThera, Alimta
15 September 2008
Alimta boosts survival in certain NSCLC types
9 June 2008
EMEA clears histology-based use for Alimta
21 April 2008
Pfizer moves to keep market share in Japan
24 March 2008
AstraZeneca enrolls vandetanib Ph III trial in NSCLC
17 March 2008
New histology-based use for Alimta
3 March 2008
Lilly's 4th qtr recovers from Zyprexa settlement
4 February 2008
UK's NICE gives go ahead on S-P's Remicade and Lilly's Alimta
28 January 2008
HGS cancer MAb's impress in trials
5 November 2007
Eli lilly sees 3rd qtr net income climb 6% as sales jump 19% to $4.6B, raises full-year guidance
29 October 2007
Lilly files Alimta with EMEA for NSCLC
1 October 2007
World Conference on Lung Cancer highlights important developments
17 September 2007
Lilly's Alimta appeal turned down by NICE committee
3 September 2007
Lilly's 2nd-qtr 20% sales hike beats estimates
30 July 2007
NICE changes course on mesothelioma drug
26 July 2007
Lilly reports benefits of Alimta in NSCLC
11 June 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
AstraZeneca begins Ph III Zactima trial
5 March 2007
Lilly's income down 81%, but shares up 1.5%
12 February 2007
Lilly reiterates 2006/07 guidance, disappoints
18 December 2006
Lilly's Almita enters Ph III trial for SCLC
30 October 2006
Lilly swings to 2nd-qtr 2006 EPS of $0.76
31 July 2006
NICE says "no" to Lilly's Alimta
10 July 2006
Lilly's Alimta 'as effective as Taxotere'
12 June 2006
Lilly's enzastaurin: good combo drug at Ph I
12 June 2006
Strong Ph II biomarker data for Lilly's Alimta
12 June 2006
Eli Lilly profit up 6% in 1st-qtr 2006
1 May 2006
Velcade enters Ph II trial in advanced NSCLC
13 March 2006
Lilly swings to 4th-qtr 2005 profit
6 February 2006
Scotland OKs Xeloda but fears in England/Wales
15 August 2005
Australian PBS adds 45 drugs, widens use for 28
8 August 2005
Lilly swings to loss in 2nd qtr on settlement
1 August 2005
Eli Lilly reports 84% income rise in 1st qtr
25 April 2005
Genasense shows strong combination performance
25 April 2005
Italy OKs 79 new drugs, plans R&D promotion
7 March 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
New product launches in 2004
31 January 2005
Lilly's Alimta OKed in EU for two indications
27 September 2004
FDA OKs 2nd indication for Lilly's Alimta
30 August 2004
Lilly's Alimta gets positive opinion in EU
5 July 2004
Lilly's Alimta cleared by FDA
16 February 2004
Stock Commentary - New York
16 February 2004
Promising new data for Lilly's Alimta
28 July 2003
Alimta has fewer side effects than Taxotere
16 June 2003
Compassionate use for Lilly's Alimta in USA
15 July 2002
Alimta: first effective mesothelioma drug
27 May 2002
Lilly's pemetrexed in mesothelioma
26 October 2001
Lilly's Zovant fast-tracked in USA
30 March 2001
Eli Lilly's once-weekly Prozac gains approval from US FDA
28 February 2001
Showing 1-92 of 92 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
